F-1/A: PomDoctor Faces Going Concern Doubt Amidst IPO Plans

PomDoctor Limited, a China-based online medical services platform, is proceeding with its initial public offering on Nasdaq despite its auditor raising substantial doubt about its ability to continue as a going concern.

Summary

• PomDoctor Limited is a Cayman Islands holding company operating primarily in China through its Variable Interest Entity (VIE), Guangzhou Qilekang Digital Health Medical Technology Co., Ltd., and its subsidiaries.
• The company is a leading online medical services platform for chronic diseases in China, ranking sixth in the Internet hospital market by contracted doctors in 2022.
• As of December 31, 2024, the company had over 212,800 contracted doctors and 699,338 transacting patients, with approximately 3.13 million prescriptions issued.
• Net revenues increased by 12.4% from RMB304.9 million in 2023 to RMB342.6 million (US$46.9 million) in 2024.
• The company incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024.
• Negative operating cash flows were RMB45.8 million in 2023 and RMB16.1 million (US$2.2 million) in 2024.
• The company had a working capital deficit of RMB112.6 million in 2023 and RMB141.6 million (US$19.4 million) in 2024.
• The auditor, Marcum Asia CPAs LLP, has expressed substantial doubt about the company's ability to continue as a going concern.
• The initial public offering aims to sell 5,000,004 American Depositary Shares (ADSs) at an estimated price range of US$4.00 to US$6.00 per ADS, representing 833,334 Class A ordinary shares (six ADSs per share).
• The company operates under a dual-class share structure, with Class B ordinary shares carrying 20 votes per share, giving Chairman and CEO Mr. Zhenyang Shi 76.0% of the aggregate voting power post-offering.
• The company has completed the required filings with the CSRC for this offering, and the CSRC published the filing results on January 17, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, evidenced by recurring net losses, negative operating cash flows, and a substantial working capital deficit, leading to a 'going concern' doubt from its auditor. While it operates in a growing industry and has some operational strengths, the fundamental financial instability and inherent risks of the VIE structure and PRC regulatory environment present considerable challenges. The IPO proceeds are intended to address some of these issues, but the underlying financial health is weak.

Positives

• Ranked sixth in China's Internet hospital market by contracted doctors in 2022, indicating a strong market position.
• Achieved high retention rates for mature doctors (99.4% in 2023 and 2024) and patient repurchase rates (63.7% in 2023, 66.2% in 2024), suggesting strong user stickiness and loyalty.
• Demonstrated revenue growth, with net revenues increasing by 12.4% from RMB304.9 million in 2023 to RMB342.6 million in 2024.
• Possesses a well-established pharmaceutical supply chain with a complete selection of medical products (42,493 SKUs in 2024) and extensive supplier channels.
• Leverages cutting-edge platform technology, including 77 software copyrights, five patents, and two patent applications, supporting efficient operations and R&D capabilities.
• Led by an experienced management team with an average of 17 years of industry experience, validated by investments from well-renowned shareholders like JD Group and Focus Media.
• Successfully completed the required cybersecurity review and CSRC filing procedures for its overseas listing.

Negatives

• The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring net losses, negative operating cash flows, and a significant working capital deficit.
• Incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024, with accumulated deficit reaching RMB2,263.4 million (US$310.1 million) as of December 31, 2024.
• Working capital deficit increased from RMB112.6 million in 2023 to RMB141.6 million (US$19.4 million) in 2024.
• The company is in an early stage of development in an emerging and dynamic industry, with historical results not indicative of future performance.
• Reliance on Variable Interest Entity (VIE) structure in China is subject to substantial uncertainties regarding interpretation and application of PRC laws, potentially leading to severe penalties or loss of control.
• The dual-class voting structure and concentration of ownership by Mr. Zhenyang Shi (76.0% voting power) limit the influence of other shareholders on corporate matters.
• The company has not been in full compliance with PRC labor laws and regulations regarding social insurance and housing provident fund contributions, potentially leading to penalties.
• Significant advertising expenses were incurred in the past (RMB221.0 million in 2020-2021) which may not be cost-effective or lead to anticipated sales levels.
• The company does not carry insurance covering medical malpractice claims and professional liability for doctors on its platform, exposing it to significant costs if claims arise.
• The company has a limited number of key suppliers, with one supplier accounting for 39.1% of total purchases in 2024, posing supply chain risks.

Risks

• Substantial doubt about the ability to continue as a going concern, risking loss of all investment.
• Maintaining customer trust is critical; any failure could severely damage reputation and brand.
• Early stage of development in an emerging and dynamic industry; historical results may not indicate future performance.
• Inability to compete effectively could materially and adversely affect business, financial condition, and results of operations.
• Improper use or disclosure of large amounts of data could harm reputation and business.
• Incurred operating losses in the past and expects to in the future; may not achieve or maintain profitability.
• Failure to drive customer engagement or provide superior customer experience could adversely affect business and reputation.
• Failure to properly manage and create value for participants in the healthcare value chain may materially and adversely affect business.
• Digital healthcare market is immature and volatile; slow development or failure to drive user engagement could harm business growth.
• Failure to attract or retain sufficient users or medical professionals for online healthcare services.
• Potential medical liability claims in connection with online healthcare services, not covered by insurance.
• Subject to penalties or disputes for failure to manage doctors on the platform in compliance with PRC regulations.
• Business involves sale of prescription drugs subject to stringent scrutiny and evolving regulations.
• Inability to develop or recoup investments in information infrastructure and technologies; failure to innovate or adapt to changing requirements.
• Self-developed technologies may contain undetected errors or not operate properly, affecting business.
• Failure to maintain optimal inventory levels could increase operating costs or lead to unfulfilled orders.
• Liability for content available in the ecosystem that is alleged to be factually incorrect, socially destabilizing, obscene, defamatory, libelous, or otherwise unlawful.
• Dependence on a limited number of key suppliers, posing supply chain risks.
• Lack of requisite approvals, licenses, or permits applicable to business may have a material adverse effect.
• Subject to a variety of laws and obligations regarding data protection; non-compliance could have a material adverse effect.
• Potential litigation, disputes, and proceedings that may materially and adversely affect reputation and financials.
• Insufficient insurance coverage could expose the company to significant costs and business disruptions.
• Inability to prevent unauthorized use of intellectual property could harm business and competitive position.
• Subject to intellectual property infringement claims, which may be expensive to defend and disrupt business.
• User growth and activity on mobile devices depend on effective use of mobile operating systems, networks, and standards not controlled by the company.
• Operations depend on the performance of Internet infrastructure and fixed telecommunications networks in China, as well as mobile operating systems and networks.
• Inability to conduct marketing activities cost-effectively and limitations in promoting business.
• Inability to detect or prevent fraud or other misconduct committed by employees or third parties.
• Reliance on assumptions and estimates to calculate key operating metrics; inaccuracies may harm reputation.
• Need for additional capital; may not be able to obtain it on favorable terms or at all.
• Not in full compliance with PRC labor laws and regulations, including social insurance and housing provident fund.
• Failure to renew current leases or locate desirable alternatives for facilities could materially and adversely affect business.
• Risks related to natural disasters, health epidemics (e.g., COVID-19), and other outbreaks.
• Trading in securities may be prohibited under the Holding Foreign Companies Accountable Act (HFCAA) if PCAOB is unable to inspect auditor in the future.
• PRC government's significant oversight and discretion over business operations could result in material adverse changes.
• Uncertainties with respect to the enforcement of laws and changes in laws and regulations in China.
• Approval and/or other requirements of the CSRC or other PRC governmental authorities may be required for offerings and future capital raising activities.
• Shareholder claims or regulatory investigations common outside China are difficult to pursue in China.
• Severe or prolonged downturn in the global economy could materially and adversely affect business.
• Dual-class voting structure limits influence of Class A shareholders and could discourage change of control transactions.
• Techniques employed by short sellers may drive down the market price of ADSs.
• No expectation to pay dividends in the foreseeable future; reliance on price appreciation for return.
• Immediate and substantial dilution for new investors due to offering price being substantially higher than net tangible book value.
• Substantial future sales or perceived potential sales of ADSs could cause price decline.
• Anti-takeover provisions in memorandum and articles of association could adversely affect shareholder rights.
• Voting rights of ADS holders are limited by deposit agreement terms; may not be able to direct voting of underlying shares.
• May not receive cash dividends if depositary deems it impractical.
• Subject to limitations on transfer of ADSs.
• Dilution of holdings due to future equity issuance and inability to participate in rights offerings.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to Cayman Islands incorporation.
• Certain judgments obtained against the company by shareholders may not be enforceable.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• No assurance of not being a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could subject U.S. investors to significant adverse tax consequences.

Future Outlook

The company plans to use the net proceeds from the IPO for supply chain stocking, expansion of departmental and geographic coverage, research and development, and general corporate purposes. It aims to continue recruiting quality doctors and attracting more patient users, enhance supply chain capabilities, invest in technology, explore new B2B patient acquisition channels, utilize big data to empower the industry, and expand into more medical areas. The company does not expect to pay cash dividends in the foreseeable future, intending to retain earnings for business development and growth.

Management Comments

• Mr. Zhenyang Shi, Chairman and Chief Executive Officer, will have considerable influence over corporate matters due to the dual-class share structure and an irrevocable voting proxy from Ms. Li Xu.
• Management's plan to alleviate substantial doubt about going concern includes obtaining new loans from banks and related parties, and attempting to improve business profitability and cash flow generation.

Industry Context

The company operates in China's rapidly expanding digital healthcare industry, particularly focusing on chronic disease management. This sector is driven by increasing health awareness, favorable government policies promoting 'Internet+ Medical Health', and the need to address unequal distribution of medical resources. The market size of China's digital healthcare industry is projected to grow from RMB540.7 billion in 2022 to RMB1,525.9 billion in 2027, representing a CAGR of approximately 23.1%. The company's focus on chronic disease management leverages the long-term, inelastic demand from patients, fostering stable doctor-patient relationships. It aims to capitalize on the transition from offline to online healthcare and the digitalization of pharmacies.

Comparison to Industry Standards

• The company ranks sixth in China's Internet hospital market by the number of contracted doctors in 2022, according to Frost & Sullivan, indicating a notable position among competitors like Medlinker, Hao Daifu, and Ping An Good Doctor.
• The company's average inventory turnover days are not explicitly compared to industry standards, but the filing notes that the average inventory turnover days of the top 5 offline pharmacies in China in 2022 were 87.8 days, compared with 26.3 days in the United States, suggesting a general industry inefficiency in China that the company's digital upgrade aims to address.
• The company's retention rate for mature doctors (99.4% in 2023 and 2024) is described as 'top-level' among the industry, suggesting strong performance in retaining key medical professionals compared to peers.
• The company's platform only provides services for follow-up patients who already have prescriptions from separate, offline services, which is a specific operational model that differentiates it from platforms offering initial diagnoses.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business, including medical disputes, fraud, misconduct, and data protection issues.

Related Party Transactions

• Zhenyang Shi (CEO) provided loans to the company with an annual interest rate of 4.90%, with balances of RMB129.5 million (2023) and RMB135.7 million (US$18.6 million) (2024) due December 31, 2026.
• Aixiangbao, a wholly-owned entity by Zhenyang Shi, assumed RMB221.0 million of advertising liability from Focus Media on behalf of the company, due August 10, 2026, with no interest.
• Li Xu (CFO and CEO's spouse) provided loans with varying interest rates (0% to 8.88%) and due dates (October 18, 2025, December 31, 2024, on demand), with balances of RMB5.0 million (2023) and RMB1.5 million (US$0.2 million) (2024).
• Aihua Peng (close relative of a shareholder's management) provided loans with a 20.00% annual interest rate, due on demand, with balances of RMB4.8 million (2023) and RMB4.0 million (US$0.6 million) (2024).
• Guoji Luo (management) provided interest-free loans due December 31, 2024 or on demand, with balances of RMB2.0 million (2023) and RMB0.8 million (US$0.1 million) (2024).
• Dexiang Wei (management) provided interest-free loans due December 31, 2024 or on demand, with balances of RMB810,045 (2023) and RMB339,450 (US$46,504) (2024).
• Yongan Zhong (management) provided a non-interest bearing loan of RMB5.0 million due on demand, with a balance of RMB2,685 (US$368) (2023 and 2024).
• Wanmei Shi (CEO's sister) provided loans with a 24.00% annual interest rate or non-interest bearing, due on demand, with a balance of RMB21,000 (US$2,877) (2024).
• The company had drug sales to Guangzhou Zhiyao Cloud Technology Co., Ltd. (a company controlled by management) of RMB123,073 (2023) and RMB1.2 million (US$0.2 million) (2024).
• The company purchased drugs from Guangzhou Aopolikang Biotechnology Co., Ltd. (a company controlled by management) of RMB142,031 (2023) and RMB25,499 (US$3,493) (2024).
• Interest expenses of loans from related parties amounted to RMB9.9 million (2023) and RMB8.6 million (US$1.2 million) (2024).

Stakeholder Impact

• **Shareholders (Existing & New):** Significant dilution for new investors due to IPO price being substantially higher than net tangible book value. Limited influence on corporate matters for Class A shareholders due to dual-class structure. Risk of losing investment if the company cannot continue as a going concern. Potential for delisting under HFCAA if auditor inspection issues recur.
• **Employees:** Equity incentives (2025 Share Incentive Plan) aim to attract and retain key personnel. However, non-compliance with PRC labor laws regarding social insurance and housing provident funds could lead to penalties or employee complaints. Job security is at risk if the company's going concern issues are not resolved.
• **Customers (Patients):** Continued access to online medical services, chronic disease management, and pharmaceutical products. Potential for improved experience through technology investments and expanded coverage. Risk of service disruption if financial or regulatory issues impact operations.
• **Doctors:** Opportunity to expand patient base and income through the platform. Risk of disciplinary action or loss of practicing licenses if not compliant with multi-institution practice regulations. Platform stability and quality of services directly impact their ability to serve patients.
• **Suppliers:** Continued business relationships, but potential for shorter credit terms due to company's efforts to accelerate inventory turnover. Risk of payment delays or reduced orders if the company's financial health deteriorates.
• **Creditors:** Significant risk due to the company's substantial working capital deficit and reliance on new loans to meet obligations. Loans from related parties and financial institutions are critical for liquidity.

Next Steps

• Complete the initial public offering and list ADSs on the Nasdaq Global Market under the symbol POM.
• Implement management's plan to alleviate going concern doubt, including improving business profitability and generating sufficient operating cash flows.
• Obtain additional working capital funds through debt and equity financings.
• Continue to recruit quality doctors and attract more patient users to the platform.
• Expand and strengthen presence in key cities and provinces across China, including implementing online medical insurance payment connections.
• Enhance supply chain capabilities by expanding product categories and supplier channels.
• Invest further in research and development to improve platform technology and AI/big data analytics.
• Explore new patient acquisition channels through enhanced B2B collaborations (e.g., with insurance companies).
• Utilize accumulated big data to empower the industry, including supporting pharmaceutical clinical trials and assisting commercial insurance companies and governmental authorities.
• Expand experience and reputation in chronic diseases to more medical areas.

Key Dates

Recommendation

The company faces severe financial challenges, including recurring net losses, negative operating cash flows, and a substantial working capital deficit, leading its independent auditor to express 'substantial doubt about its ability to continue as a going concern.' While the IPO aims to raise capital, the amount is relatively small compared to the accumulated deficit and ongoing cash burn. The inherent risks of the VIE structure in China, coupled with evolving and uncertain PRC regulatory oversight, add significant legal and operational uncertainty. The dual-class share structure concentrates voting power, limiting minority shareholder influence. For a seasoned investor, the fundamental financial instability and high operational risks outweigh the potential for growth in the digital healthcare market, making the investment highly speculative with a significant risk of capital loss.

Keywords

Online Medical Services, Chronic Disease Management, Internet Hospital, Pharmaceutical Supply Chain, China Healthcare, Telemedicine, Digital Health, SEC Filing, IPO, VIE Structure, Going Concern, Nasdaq, Cayman Islands, PRC Regulation, American Depositary Shares, ADS